District of Columbia Code
Subchapter II - Access to Treatment for Anaphylaxis
§ 7–2381.03. Authorized use

An employee or agent of an authorized entity who has completed the training program described in § 7-2381.04 may use an epinephrine auto-injector prescribed pursuant to § 7-2381.02 to:
(1) Provide an epinephrine auto-injector to any individual who the employee or agent believes in good faith is experiencing anaphylaxis, for immediate administration;
(2) Provide an epinephrine auto-injector to the parent, guardian, or caregiver of an individual who the employee or agent believes in good faith is experiencing anaphylaxis, for immediate administration; or
(3) Administer an epinephrine auto-injector to any individual who the employee or agent believes in good faith is experiencing anaphylaxis.
(Feb. 22, 2019, D.C. Law 22-207, § 4, 65 DCR 12365.)
Applicability of D.C. Law 22-207: § 7155 of D.C. Law 23-16 repealed § 10 of D.C. Law 22-207. Therefore the creation of this section by D.C. Law 22-207 has been implemented.
Applicability of D.C. Law 22-207: § 10 of D.C. Law 22-207 provided that the creation of this section by § 4 of D.C. Law 22-207 is subject to the inclusion of the law’s fiscal effect in an approved budget and financial plan. Therefore that amendment has not been implemented.
For temporary (90 days) repeal of applicability provision of D.C. Law 22-207, see § 7155 of Fiscal Year 2020 Budget Support Congressional Review Emergency Act of 2019 (D.C. Act 23-112, Sept. 4, 2019, 66 DCR 11964).
For temporary (90 days) repeal of applicability provision of D.C. Law 22-207, see § 7155 of Fiscal Year 2020 Budget Support Emergency Act of 2019 (D.C. Act 23-91, July 22, 2019, 66 DCR 8497).

Structure District of Columbia Code